FDA Brief

Warning letters Drugs

FDA warning letter to

FWD Care, Inc. dba FWD

MediumIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.

What happened

FDA reviewed the company's website, https://fwd.care, in August 2025 and found it offering compounded drug products including semaglutide and tirzepatide (GLP-1 drugs, a class of medicines used for weight loss and diabetes). The site told customers its products had the "same active ingredients" as Wegovy, Ozempic, Zepbound and Mounjaro. FDA said those statements wrongly suggest the compounded products are the same as FDA-approved drugs, when compounded drugs are not FDA-approved.

What FDA found

  1. The website said its compounded drugs have the same active ingredients as branded FDA-approved drugs, which falsely implies they are the same product.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. Advertising or promotion for a compounded drug that is false or misleading in any way makes the drug misbranded.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. Sending these misbranded drugs across state lines is a prohibited act.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. Receiving misbranded drugs in interstate commerce and delivering them is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]
  5. The semaglutide and tirzepatide products are "new drugs" not generally recognized as safe and effective for their labeled uses.

    FDCA section 201(p) [21 U.S.C. § 321(p)]

What FDA wants

FDA tells the company to immediately stop using the misleading language and, within 15 working days of receiving the letter, send the Office of Compounding Quality and Compliance a written account of each corrective step with supporting documents. If the work cannot be finished in that time, the company must say why and give a date for completion.

Who should pay attention

  • telehealth platforms selling compounded GLP-1 weight-loss drugs
  • compounding pharmacies that supply or partner with such platforms
  • marketing and compliance staff who write drug promotional claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low